We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study.
Amgen has terminated its collaboration with Cytokinetics and intends to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.